Bispecific CAR T-cell therapy yields complete responses in relapsed/refractory non-Hodgkin lymphomasJune 21, 2019B Cell LymphomaMantle Cell Lymphoma
5F9 plus rituximab take a bite out of drug-resistant NHLJune 18, 2019B Cell LymphomaFollicular Lymphoma
Obinutuzumab provides strong early responses in untreated MCLJune 17, 2019Mantle Cell LymphomaB Cell Lymphoma
Inhibitor produces high response rate in relapsed/refractory FLJune 11, 2019Follicular LymphomaB Cell Lymphoma
Fixed-duration venetoclax-obinutuzumab superior to standard CLL therapyJune 7, 2019CLLB Cell Lymphoma
Venetoclax plus ibrutinib appears to suit elderly and high-risk patients with CLLMay 29, 2019CLLB Cell Lymphoma
FDA approves lenalidomide/rituximab for previously treated FL, MZLMay 29, 2019B Cell LymphomaFollicular Lymphoma
